Navigation Links
UNC team finds new target for treatment of advanced prostate cancer
Date:7/6/2010

Chapel Hill, NC In its early stages, prostate cancer requires androgens (hormones that promote the development and maintenance of male sex characteristics) for growth, and current first-line therapies target the receptor for these hormones to slow cancer's development and spread.

However, advanced prostate cancers are often androgen-independent, meaning that androgen-blocking therapies are ineffective.

Scientists aren't sure how this shift occurs as prostate cancer advances. One idea is that prostate cancer cells acquire the ability to make their own androgen. Another says that the androgen receptor that is known to stimulate tumor growth can still be active even when the hormone is not present. Most likely, both are important.

A recent study by UNC researchers, published in the Journal of Biological Chemistry, provides evidence for the second theory, demonstrating that expression of one of a group of genes found only in humans and non-human primates can promote androgen receptor activity in concert with other proteins called coregulators.

One of a group of MAGE genes, so named because they were originally identified in melanoma, called MAGE-11 interacts with another protein, called p300, to provide the cancer cells with a way to enhance androgen receptor signaling and promote tumor growth, even when patients are undergoing androgen deprivation therapy.

According to team leader Elizabeth M. Wilson, PhD, professor of pediatrics and biochemistry and biophysics at UNC-Chapel Hill, "We found that a small portion of the androgen receptor interacts with the MAGE-11 molecule which serves as a bridge to p300, a strong histone modifying enzyme that increases androgen receptor activity. This is exciting because it shows how the cancer cells have developed a way to boost androgen receptor activity, even in the absence or at low levels of the hormone that binds the androgen receptor."

Wilson, who is also a UNC Lineberger member, goes on to explain that understanding this mechanism opens the door to additional targets for new therapies and broader clinical applications of new drugs.

"The MAGE-11 molecule is a promising target for shutting down androgen receptor activity that promotes the growth of cancer cells," she adds.


'/>"/>

Contact: Ellen de Graffenreid
edegraff@med.unc.edu
919-962-3405
University of North Carolina School of Medicine
Source:Eurekalert

Related biology news :

1. University of Oregon researcher finds that on waters surface, nitric acid is not so tough
2. Study finds environmental tests help predict hospital-acquired Legionnaires disease risk
3. Study finds blocking angiogenesis signaling from inside cell may lead to serious health problems
4. Study finds Viagra increases release of key reproductive hormone
5. Survey finds elevated rates of new asthma among WTC rescue and recovery workers
6. St. Jude finds factors that accelerate resistance to targeted therapy in lymphoblastic leukemia
7. Study finds a high rate of asthma in college athletes
8. Ecologist finds dire devastation of snake species following floods of 93, 95
9. Men shed light on the mystery of human longevity, study finds
10. JILA finds flaw in model describing DNA elasticity
11. Americans remain pessimistic about the environment, Stanford-AP survey finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2016)... NEW YORK , June 2, 2016   The ... (Weather), is announcing Watson Ads, an industry-first capability in which ... advertising, by being able to ask questions via voice or ... Marketers have long ... with the consumer, that can be personal, relevant and valuable; ...
(Date:5/24/2016)... IRVINE, Calif. , May 24, 2016 Ampronix facilitates superior patient care ... LMD3251MT  3D medical LCD display is the latest premium product recently added to ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com , ... published the overview results from the Q1 wave of ... recent wave was consumers, receptivity to a program where ... with a health insurance company. "We were ... share," says Michael LaColla , CEO of Troubadour ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
(Date:6/23/2016)... NEW YORK , June 23, 2016 ... the trading session at 4,833.32, down 0.22%; the Dow Jones ... the S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ... BIND Therapeutics Inc. (NASDAQ: BIND ). Learn more ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, ... tools designed, tuned and optimized exclusively for Okuma CNC machining centers at The ... of a collaboration among several companies with expertise in toolholding, cutting tools, machining ...
(Date:6/22/2016)... , June 22, 2016 Cell Applications, ... allow them to produce up to one billion ... lot within one week. These high-quality, consistent stem ... preparing cells and spend more time doing meaningful, ... a proprietary, high-volume manufacturing process that produces affordable, ...
Breaking Biology Technology: